Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.9K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.9K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Association between comorbidities and major adverse cardiovascular events in patients undergoing immune checkpoint blockade.

BMC cancer·2026
Same author

Long-Term Outcomes From a Decade of Donation After Circulatory Death Heart Transplantation in Australia.

JACC. Heart failure·2026
Same author

Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.

JHLT open·2026
Same author

Decoding sex and gender effects on health: evidence from a nationwide cohort.

Biology of sex differences·2026
Same author

Left ventricular function and its longitudinal change in Swiss childhood cancer survivors - results from the CardioOnco study.

Cardio-oncology (London, England)·2026
Same author

AI-echocardiography: an eagle eye for the prognostic staging of ATTR cardiomyopathy.

European journal of heart failure·2026

相关实验视频

Updated: May 6, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.3K

矿物质皮质类受体的抑制改善了转向心肌衰竭的过程,并减少了患有慢性压力过载的小鼠的氧化应激和炎症.

Gabriela M Kuster1, Eugene Kotlyar, Mary K Rude

  • 1Cardiovascular Medicine Section, Boston University Medical Center, Boston, Mass, USA.

Circulation
|February 3, 2005
PubMed
概括
此摘要是机器生成的。

矿物质皮质类受体对手eplerenone改善了生存率,并减轻了慢性压力过载的小鼠的不良心脏重塑. 这些发现突显了矿物质皮质类受体在心力衰竭进展中的作用.

更多相关视频

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.6K
Chronic Stress Shifts Effort-Related Choice Behavior in a Y-Maze Barrier Task in Mice
09:37

Chronic Stress Shifts Effort-Related Choice Behavior in a Y-Maze Barrier Task in Mice

Published on: August 13, 2020

10.9K

相关实验视频

Last Updated: May 6, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.3K
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.6K
Chronic Stress Shifts Effort-Related Choice Behavior in a Y-Maze Barrier Task in Mice
09:37

Chronic Stress Shifts Effort-Related Choice Behavior in a Y-Maze Barrier Task in Mice

Published on: August 13, 2020

10.9K

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 在高血压模型中,阿尔多斯特通过矿物质皮质类受体诱导左心室 (LV) 缩.
  • 矿物质皮质体受体在慢性压力过载的不利重塑中的作用在很大程度上是未知的.

研究的目的:

  • 调查矿物质皮质类受体在调解从LV增大到心力衰竭的过渡中的作用.
  • 在慢性压力过载的小鼠模型中评估矿物质皮质类受体选择性对抗剂eplerenone (EPL) 的疗效.

主要方法:

  • 小鼠经历了上升的大动脉收缩 (AAC) 诱导慢性压力过载.
  • 在AAC之后,小鼠接受了7周的常规或含有eplerenone (EPL) 的治疗.
  • 评估了心脏功能,尺寸,纤维化,亡,氧化应激和炎症标志物.

主要成果:

  • 在AAC后,EPL治疗显著改善了生存率 (94%vs65%).
  • EPL减弱了LV尺寸的增加,并保留了分数缩短.
  • EPL减少了心肌纤维化,肌细胞亡,氧化应激和炎症细胞透.

结论:

  • 矿物质皮质类皮质受体在调解慢性压力过载下从LV缩到心力衰竭的过渡过程中至关重要.
  • 埃普莱伦的有益作用包括缓解间歇性矩阵变化,肌细胞亡,氧化应激和炎症.